Despite the Dow losing 1500 pts since August Pfizer seems to be showing relatively good strength. It's held up quite well in the recent turbulence. While I stopped charting and technical analysis long ago, I think it's worth looking at the fundamentals of this company again.
Despite the patent expiry issues the balance sheet is still strong and big pharma normally should not suffer heavily in a US recession as people will still buy drugs whether the economy is good or bad, plus they have a strong global presence. Healthcare is a major issue in current US presidential election debates and the Democrats look set at instituting some serious reforms in that sector once they start to progressively curtail spending in Iraq
This is a good defensive play currently yielding over 5%. Dividends have been paid since 1901.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment